'We cannot stay silent': Novo Nordisk flags dangers of compounded GLP-1s following Hims & Hers Super Bowl ad
The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain dangerous impurities, banned substances, or incorrect doses.” Toward the bottom, the ad urges readers to “get the facts” from Novo's own web page about semaglutide.
Scripps News on MSN18h
Hims and Hers likely to stop selling cheaper versions of GLP-1 medicationsThe FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...
The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...
Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...
Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...
Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...
Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...
Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback